73 Ocean Street, New South Wales 2000, SYDNEY

Contact Person: Callum S Ansell
E: [email protected]
P: (02) 8252 5319


22 Guild Street, NW8 2UP,

Contact Person: Matilda O Dunn
E: [email protected]
P: 070 8652 7276


Genslerstraße 9, Berlin Schöneberg 10829, BERLIN

Contact Person: Thorsten S Kohl
E: [email protected]
P: 030 62 91 92

Recombinant DNA Technology

Recombinant DNA Technology

The Research Program on Recombinant DNA Technology, Genes, Environment and Health began in 2000 as a collaboration of research scientists. The collaborating program conducts research on genetic and environmental influences on a wide variety of health conditions and diseases.  The program began with a survey of close to 2 million adult which 600,000 completed the survey, providing data on demographics, health behavior and health history. The program built a secure database with relevant health and environmental information.

Recombinant DNA technology has been effectively used to produce various human proteins in microorganisms, such as insulin and growth hormone, used in the treatment of diseases.

The program will involve the manufacturing of recombinant human insulin which is manufactured in different doses for therapeutic action (insulin lispro, insulin as part, insulin glargine, with very fast, long-acting, respectively) and for different modes of administration.

The research program on Recombinant DNA Technology is planning, it’s second phase to address engagements with national laboratories, hospitals, clinics and municipalities. The program will continue its work as a research program, using large-scale genetic, molecular, environmental and health information developed to enable research on important questions about environment, technology, disease and health.

80 recombinant DNA based products had been approved for treating disease and for vaccination.
350 recombinant DNA-based drugs have been tested for safety and efficacy.
Improves plants' resistance to pests and increase crop yields.
Recombinant insulin has a superior level of purity and consistent quality compared with semisynthetic insulin.
Recombinant DNA technology enables the manufacture of proteins and antibodies with a defined specificity and uniformity.


  • Guidance in the medical field and governments towards rDNA technology.
  • Provide medical solutions, accessing loans and other funding sources.
  • Help with the manufacturing of recombinant human insulin.
  • Provide medical resources to low-income communities.
  • Improve agriculture with the usage of rDNA technology (pests control and increase crop yields).